Santhera Pharmaceuticals (schweiz) Ag

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Renata Ag

Santhera Pharmaceuticals Ag

Thomas Meier

Bibiana Bielekova

Henry McFarland

Eric Weber

Markus A Rüegg

Urs Renggli

Gunnar Buyse

Markus A Ruegg

Henry F Mcfarland

The invention relates to a blister pack () for a button battery, comprising a blister foil () designed to form at least one housing for receiving at least one button battery, and integral with a base (). According to the invention, the blister pack comprises, between the base () and the blister foil (), a reinforcing foil () which has inter alia a tensile strength of between 1,200 kg/cmand 3,100 kg/cmaccording to the ASTM D 882 standard. Moreover, an orifice opening into the hosung is provided.

Blister pack for button battery

The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.

Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis

The invention relates to the use of a compound of the formula (I) or a pharmaceutically acceptable addition salt thereof for the preparation of a medicament for the prophylaxis and/or treatment of muscular dystrophy.

Use of N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of muscular dystrophy

Use of idebenone for the preparation of a medicament for the treating of a muscular dystrophy in particular for treating and/or preventing weakness and/or loss of skeletal muscle tissue and/or cardiomyopathy associated with a muscular dystrophy.

Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of muscular dystrophies

The invention relates to a method of treating muscular dystrophy, such as a muscular dystrophy or myopathy resulting from mutations in genes encoding collagen VI, in a mammal. The method involves administering of a compound of the formula (I) or a pharmaceutically acceptable addition salt thereof to the mammal.

N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency

Growing community of inventors

Basel, Switzerland

Thomas Meier